Beyond alpha-glucosidase, alpha-amylase, and other starch blockers widely exploited for antidiabetic drug development (Ogunyemi et al. 2020), the dipeptidyl peptidase-4 (DPP-4) enzyme is an emerging drug target and has been recommended in the treatment of diabetes as it acts in carbohydrate metabolism by delaying gastric emptying, increasing insulin secretion, and reducing glucagon secretion (Nauck 2016, Kanwal et al. 2022). Here, DPP4 is linked to diabetes mellitus.